Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Fudan University
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05172999CT.gov Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infertility Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegloxenatide (this asset) | Fudan University | P2/3 | B · 61 |
| Clomiphene Citrate | Sana'a University | P4 | A |
| Metformin | Peking University Third Hospital | P4 | A |
| Letrozole | GABRIEL MONTEIRO PINHEIRO | P4 | BBB |
| Human Chorionic Gonadotropin | Damascus University | P4 | BBB |
| Cetrotide | Fayoum University | P4 | BBB |
| Follitropin Beta | Ferring Pharmaceuticals | P4 | BBB |
| Urofollitropin | Mansoura Integrated Fertility Center | P4 | BBB |
| Recombinant Fsh | Damascus University | P4 | BB |
+35 more in the Infertility Disorder cohort
Other indications for Pegloxenatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atypical Endometrial Hyperplasia | — | P2/3 | B · 61 |
| Obesity Disorder | — | P2/3 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegloxenatide in Infertility Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/peg-loxenatide-infertility-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →